In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
- Provide List Of Schizophrenia Care Centres In And Around Delhi: Delhi High Court Directs Delhi Govt., AIIMSon April 19, 2021 at 2:29 am
The Delhi High Court last week asked the Delhi Government and the All India Institute of Medical Sciences (AIIMS) to submit details about the facilities available in and around the ...
- Global Schizophrenia Drugs Market By Type, By Application, By Segmentation, By Region, and By Country 2021on April 18, 2021 at 10:17 pm
The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market ...
- Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophreniaon April 18, 2021 at 5:20 pm
Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced results from its Phase 2 ...
- Lyndra's ultralong-acting pill shows promise in schizophrenia phase 2, teeing up pivotal trialon April 18, 2021 at 1:20 pm
In a phase 2 study, patients taking Lyndra Therapeutics’ once-weekly schizophrenia pill, LYN-005, quickly reached therapeutic levels of the drug, according to data presented virtually Sunday at the ...
- FXR1 regulation of parvalbumin interneurons in the prefrontal cortex is critical for schizophrenia-like behaviorson April 16, 2021 at 1:59 am
Parvalbumin interneurons (PVIs) are affected in many psychiatric disorders including (SCZ), however the mechanism remains unclear. FXR1, a high confident risk gene f ...
- Genetic predisposition to schizophrenia may increase risk of psychosis from cannabis useon April 15, 2021 at 11:18 am
New research shows that while cannabis users had higher rates of psychotic experiences than non-users across the board, the difference was especially pronounced among those with high genetic ...
- Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trialon April 14, 2021 at 2:08 am
Clinically stable, overweight (body mass index (BMI) > 25) patients (ages 17–45) within 5 years of a DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder, or under the age ...
- Understanding Injection Options for Schizophrenia Treatmenton April 14, 2021 at 12:13 am
One treatment option for schizophrenia is long-acting injections. Learn more about what they are and how they work to consider whether they’re an option for you.
- In the News: Schizophrenia may increase the risk of death from COVID-19on April 6, 2021 at 1:30 pm
Research suggests that people with schizophrenia are at increased risk of contracting and dying of SARS-CoV-2, the virus that causes COVID-19. The relationship between COVID-19 and mental health is ...
via Bing News